RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Breast cancer treatment: perspectives on the oncolytic virusWhat is beginning to be better understood is that PD1 drugs alone are not a panaceas to an effective canxer treatment since approximately only 20-30% of the patients treated respond. What has been identified as a significant issue can be simply described as an immunosuppressed tumor microenvironment (TME) and insufficient level of TiLs and CD+8 cells that leads to T-cell exhaustion which are both critical for PD-L1 checkpoint inhibitors to become effective, and require to be reversed. ONCY's pelareorep has demonstrated that it is capable of remodeling the TME and stimulating the upregulation of TiLs and CD+8 cells in advance of PD-L1 administration, thus "priming" the immune system for the synergistic addition of a checkpoint inhibitor.
What is now being understood is that the immune system requires to be 'primed' in a way that the immune system becomes ready for the addition of checkpoint inhibitor in order for these inhibitors can work effectively. ONCY's GOBLET-1 study showed that pelareorep it is able to prime the immune system in advance of the synergistic addition of an immune checkpoint inhibitor, like Tecentriq. This form of "priming" the immune system before the addition of an other I/O agent is now being recognized more widely now as the best way of delivering combination I/O therapies for an effective result to occur. ONCY has been successfully demonstrating this sequencing in multiple clinical trials that are now late stage development.